Core Viewpoint - UC Asset Limited Partnership (UCASU) supports President Trump's decision to reschedule marijuana from Schedule I to Schedule III, marking a significant deregulation for the cannabis industry [1] Group 1: Company Overview - UC Asset is one of only four US public companies focused on investing in cannabis properties, claiming to have the "best performing" cannabis property portfolio among its peers [2] - The company has nearly doubled its cannabis property portfolio from $1.6 million to $3.1 million earlier this year [3] Group 2: Investment Strategy - UC Asset has developed an investment plan anticipating a policy breakthrough in the cannabis industry, which has guided its recent acquisitions [3] - The company has filed for a $5 million Secondary Public Offering (SPO) to acquire two additional cannabis properties, with plans to launch fundraising in March 2026 [4] - In addition to the SPO, UC Asset is selling about $3 million of its legacy assets and exploring other financing options, aiming to expand its cannabis portfolio by 400% to approximately $12 million in 2026 [5] Group 3: Performance Metrics - UC Asset reports a 14.4% Return on Investment (ROI) for its cannabis portfolio, significantly above the industry average and outperforming similar portfolios held by other public companies [6] - The company projects its cannabis portfolio will maintain an ROI between 13.5% and 14.5% for 2025, with potential increases above 15% in 2026 [7]

Core Thesis - Tilray Brands, Inc. is positioned for growth through diversification and international expansion, with a focus on cannabis, beverage, and medical products [2][3][6] Financial Performance - Q4 revenue grew 25% year-over-year to $229.9 million, with beverage sales surpassing cannabis revenue for the first time [2] - Q3 2025 results showed revenue of $209.5 million and non-GAAP breakeven EPS, leading to a 22% intraday share price increase [6] Strategic Initiatives - The company acquired four craft breweries from Molson Coors and introduced new cannabis strains in Canada, indicating a commitment to strategic growth [3] - Tilray expanded its medical cannabis programs and obtained new cultivation and trading licenses in Germany, while launching additional products in Portugal and Canada [2] Market and Regulatory Environment - Political developments in 2024, including potential cannabis deregulation under the Trump administration, created speculation around federal reform [3][5] - Despite Florida voters rejecting a legalization amendment, there is sector-wide optimism regarding easing restrictions and potential banking access for cannabis firms [4] Investor Sentiment - A 14% post-market surge in Tilray shares followed signals from the Trump administration regarding potential cannabis reclassification, renewing investor interest [5] - The company is seen as having a compelling risk/reward profile due to a stronger revenue mix, improving balance sheet, and favorable policy sentiment [6]